Maximus (NYSE:MMS – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
Maximus Price Performance
Shares of NYSE:MMS traded down $0.39 on Thursday, reaching $72.50. 1,701,725 shares of the company traded hands, compared to its average volume of 408,183. Maximus has a fifty-two week low of $71.75 and a fifty-two week high of $93.97. The company’s 50 day moving average is $87.17 and its 200-day moving average is $87.75. The stock has a market capitalization of $4.37 billion, a PE ratio of 14.50 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.49 and a quick ratio of 1.49.
Insider Activity
In other news, insider Michelle F. Link sold 1,363 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $92.56, for a total value of $126,159.28. Following the completion of the sale, the insider now owns 6,567 shares in the company, valued at $607,841.52. This represents a 17.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.40% of the company’s stock.
Institutional Trading of Maximus
About Maximus
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Featured Articles
- Five stocks we like better than Maximus
- Insider Trading – What You Need to Know
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Breakout Stocks: What They Are and How to Identify Them
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Stock Average Calculator
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.